COMPANY PROFILE - Menarini Group
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
COMPANY PROFILE CORPORATE PRESENTATION - NOT FOR PROMOTION
COMPANY PROFILE 1/17
Menarini was
founded in 1886.
In 1915 its headquarters
were established
in Florence.
CORPORATE PRESENTATION - NOT FOR PROMOTION
COMPANY PROFILE 2/17
Milestones
1886 1964 1978 1992 2003
MENARINI INTERNATIONAL RESEARCH & CENTRAL AND MENARINI
FOUNDATION PRESENCE DEVELOPMENT EASTERN EUROPE BIOTECH
The internationalisation Menarini’s Research & Menarini acquires ex-GDR Opening of Menarini Biotech,
of Menarini begins Development department company Berlin-Chemie specialised in the research,
with the opening of opened and patents on thanks to which it makes its development and
Laboratorios Menarini pharmaceuticals were entry into Germany and manufacturing of biotech
in Spain, followed on by introduced. Central and Eastern Europe. pharmaceuticals,
Greece, Portugal, Central from the lab to the patient.
America and France.
CORPORATE PRESENTATION - NOT FOR PROMOTION
COMPANY PROFILE 3/17
Milestones
2011 2013 2016 2020
ASIA SILICON
CELLSEARCH U.S.A.
PACIFIC BIOSYSTEMS
Menarini makes its entry into Acquisition of Acquisition of Cell Search, Menarini makes its entrance into the
Asia Pacific thanks to the Silicon Biosystems, an FDA approved technology USA thanks to the acquisition of
acquisition of a company a start-up of in the field of circulating Stemline, biopharmaceutical
based in Singapore and innovative technologies tumour cells. company publicly listed on NASDAQ,
present in 13 countries for liquid biopsies. and their product Elzonris, the only
throughout the region, from FDA approved therapy available for
China to Australia. BPDCN, thus strengthening
Menarini’s presence in oncology.
CORPORATE PRESENTATION - NOT FOR PROMOTION
COMPANY PROFILE 4/17
Consolidated turnover
Million euro
3,750
4.000
Menarini ranking* 3,527
3.500
32nd Global position 3,212
3.000
15th European position 2,620
2.500
1,869
2.000
1,306
1.500
1.000
794
500
1 13
0
1964 1978 1992 2000 2004 2008 2012 2016 2020
Source: internal data. *Source : Iqvia WRMP 12/2020 - Retail Market.
CORPORATE PRESENTATION - NOT FOR PROMOTION
COMPANY PROFILE 5/17
Consolidated turnover
Pharmaceutical 92% Abroad 76%
Diagnostic 7% Other 1% Italy 24%
Source: internal data.
CORPORATE PRESENTATION - NOT FOR PROMOTION
COMPANY PROFILE 6/17
Menarini in the WORLD
Present in 140 countries worldwide (with its affiliates, distributors and franchises).
CORPORATE PRESENTATION - NOT FOR PROMOTION
COMPANY PROFILE 7/17
Western Europe
9,400 employees
Presence
Florence - Italy (headquarters), Austria, Belgium,
Cipro, France, Germany, Greece, Ireland, Luxembourg,
Portugal, Spain, Sweden**, Switzerland, Netherlands**,
Turkey and United Kingdom.
Source: internal data. **Menarini Diagnostics presence.
CORPORATE PRESENTATION - NOT FOR PROMOTION
COMPANY PROFILE 8/17
Central & Eastern Europe
3,400 employees
Presence
Berlin (headquarters), Albania, Armenia, Azerbaijan,
Belarus, Bosnia&Herzegovina, Bulgaria, Czech Republic,
Croatia, Estonia, Finland, Georgia, Hungary, Kazakhstan,
Kyrgystan, Kosovo, Latvia, Lithuania, Moldova, Mongolia,
Montenegro, North Macedonia, Poland, Romania, Russia,
Serbia, Slovak Republic, Slovenia, Turkmenistan, Ukraine,
Uzbekistan.
Source: internal data.
CORPORATE PRESENTATION - NOT FOR PROMOTION
COMPANY PROFILE 9/17
Asia Pacific
3,600 employees
Presence
Singapore (headquarters), China, India, Australia,
South Korea, Taiwan, Thailand, the Philippines, Indonesia,
Vietnam, New Zealand, Hong Kong and Malaysia.
Distributors – Japan: Menarini Silicon Biosystems presence.
Source: internal data.
CORPORATE PRESENTATION - NOT FOR PROMOTIONCOMPANY PROFILE 10/17
U.S.A.
acquisition June 2020
ELZONRIS® For the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN),
(tagraxofusp) commercially available in the US. In Europe, on January 2021 Elzonris has
been approved by the EMA as monotherapy for the first-line treatment of
adult patients with BPDCN.
Tagraxofusp is also being evaluated in other CD123+ indications, including chronic myelomonocytic
leukemia (CMML), and myelofibrosis (MF).
Other products in Pipeline
SL-701 Immunotherapy in phase II for patients with glioblastoma multiforme.
Felezonexor XPO1 inhibitor in phase I for patients with advanced solid tumors.
SL-901 PI3K inhibitor in phase I for patients with solid tumors.
SL-1001 RET kinase inhibitor in preclinical development. Location: New York, U.S.A.
CORPORATE PRESENTATION - NOT FOR PROMOTIONCOMPANY PROFILE 11/17
North America
Menarini Group’s lead company in the high-tech diagnostics area.
The main instruments, DEPArray™, Ampli 1™ and CELLSEARCH® are used
in personalized oncological therapies to find possible tumor mutations thoroughly
and individually, and to determine the best therapy for the patient.
All this from a simple blood sample.
Locations: Philadelphia, U.S.A.
Bologna, ITALY
CORPORATE PRESENTATION - NOT FOR PROMOTIONCOMPANY PROFILE 12/17
Number of employees
20.000
17,650
18.000
16.000
14.000
12,900
12.000
10.000
7,950
8.000
6.000
3,600
4.000
2.000
188
0
1964 1990 2000 2010 2020
Source: internal data.
CORPORATE PRESENTATION - NOT FOR PROMOTIONCOMPANY PROFILE 13/17
Employees % of graduates and technicians
100
91%
90
80 72%
70
60
50
40
30
20
10%
10
0
1964 1990 2020
CORPORATE PRESENTATION - NOT FOR PROMOTIONCOMPANY PROFILE 14/17
18 production plants
In 2020 these sites produced 572 million packs of pharmaceuticals products.
Ireland *
Russia *
Shannon Kaluga
USA **
Spain Turkey *
Indonesia *
Philadelphia (Huntingdon Valley) Barcelona Istanbul Jakarta
Italy
Central America *
Germany Pisa (2 plants), Florence (2 plants and 1 plant under construction), Pomezia***, L'Aquila,
Guatemala City Berlin (2 plants), Dresda Lomagna (Lecco), Casaletto Lodigiano (Lodi), Rapolano (Siena) plant nearing completion
* Plants dedicated to production for local markets. ** Diagnostic production. ***Biotech manufacturing with development and production processes also for third parties.
CORPORATE PRESENTATION - NOT FOR PROMOTIONCOMPANY PROFILE 15/17
10 Research & Development centres
915 employees
Barcelona Florence
New York Pisa Rome
**
Philadelphia Berlin Siena Bologna
*
Singapore
* Rapolano. **Pomezia.
CORPORATE PRESENTATION - NOT FOR PROMOTIONCOMPANY PROFILE 16/17
Research & Development Projects ONCOLOGY
COMPOUND DRUG CLASS (TARGET) INDICATION DEVELOPMENT STAGE
Tagraxofusp (Elzonris®) TB (CD123) Blastic plasmacytoid dendritic cell neoplasm EMA and FDA: approved
Tagraxofusp TB (CD123) Chronic myelomonocytic leukemia Phase II
Tagraxofusp TB (CD123) Myelofibrosis Phase II
Elacestrant* SERD (ER) Breast cancer Phase III
SL-701 IT (IL-13Rα2, EphA2, Survivin) Glioblastoma Multiforme Phase II
MEN1703 SME (PIM/FLT3i) Acute myeloid leukaemia Phase II
MEN1611 SME (PI3Ki) Breast cancer Phase Ib
MEN1611 SME (PI3Ki) Colorectal cancer Phase Ib
MEN1112 mAB (Anti-CD157) Acute myeloid leukaemia Phase Ib
MEN1309 ADC (Anti-CD205) Solid tumours Phase Ib
Felezonexor SME (XPO1i) Solid tumours Phase Ib
SL-901 SME (PI3Ki) Solid tumours Phase Ia
SL-1001 SME (RETi ) Solid tumours Preclinical
*developed by Radius Health; TB, Targeted Biologic; SERD, Selective Estrogen Receptor Degrader; IT, Immunotherapy; SME, Small Molecule Entity; mAB, Monoclonal Antibody; ADC, Antibody Drug Conjugate.
CORPORATE PRESENTATION - NOT FOR PROMOTIONCOMPANY PROFILE 17/17
Research & Development Projects ANTI-INFECTIVES
COMPOUND DRUG CLASS INDICATION DEVELOPMENT STAGE
Complicated urinary tract infections,
Meropenem + Carbapenem + Complicated Intra abdominal infections,
EMA and FDA: approved
Vaborbactam β-lactamase inhibitor Hospital acquired pneumonia, Ventilator
associated pneumonia and Bacteremia
Acute Bacterial Skin and Skin
Delafloxacin Anionic fluoroquinolone
Structure - ABSSSI
EMA and FDA: approved
Community Acquired
Delafloxacin Anionic fluoroquinolone
Bacterial Pneumonia - CABP
EMA and FDA: approved
Acute Bacterial Skin and Skin
Oritavancin Semisynthetic glycopeptide
Structure - ABSSSI
EMA and FDA: approved
Acute Bacterial Skin and Skin
Oritavancin Semisynthetic glycopeptide
Structure - ABSSSI
Phase Ib (new formulation)
*On April 2021, Delafloxacin has been approved in EU for the for the treatment of CABP.
CORPORATE PRESENTATION - NOT FOR PROMOTIONCORPORATE PRESENTATION - NOT FOR PROMOTION
You can also read
